biostudies-literatureBilen OBristol-Myers Squibbe005502https://www.ebi.ac.uk/biostudies/studies/S-EPMC12915557biostudies-literatureUnknown19(1)<h4>Background</h4>Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II-III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest that mavacamten monotherapy is efficacious and has a favorable safety profile, but limited evidence exists regarding monotherapy in real-world studies. This analysis aimed to describe the effectiveness and safety outcomes of mavacamten monotherapy in the real-world COLLIGO-HCM study (Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy).<h4>Methods</h4>Patient-level data recorded between April 2022 and February 2025 at 7 sites across 5 countries were extracted. Adult patients with a diagnosis of HCM from 2018 onwards were eligible for Circulation. Genomic and precision medicineMavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM.PMC12915557N/ASandler BPruett CMacNamara JPMaksabedian Hernandez EJHan XTian DBurford EAdler AMaor ELi LPatel NArora PBilen OSchuler PCOLLIGO-HCM investigatorsArora GParatz EGold MArad MBastiaenen RfalseMavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM.<h4>Background</h4>Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II-III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest that mavacamten monotherapy is efficacious and has a favorable safety profile, but limited evidence exists regarding monotherapy in real-world studies. This analysis aimed to describe the effectiveness and safety outcomes of mavacamten monotherapy in the real-world COLLIGO-HCM study (Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy).<h4>Methods</h4>Patient-level data recorded between April 2022 and February 2025 at 7 sites across 5 countries were extracted. Adult patients with a diagnosis of HCM from 2018 onwards were eligible for 2026-01-01T00:00:00Z2026 Feb2026-07-16T06:58:12.919Z2026-07-09T13:10:59.673ZS-EPMC129155574121216810.1161/CIRCGEN.125.005502